{
  "id": 10932617,
  "title": "Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer",
  "url": "https://urgent.news/2026/09/30/arbutus-announces-preliminary-results-of-its-us-230-million-modified",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T11:35:47.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/arbutus-announces-preliminary-results-of-its-us230-million-modified-dutch-auction-tender-offer"
  },
  "original_language": "en",
  "account": null,
  "summary": "WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the preliminary results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}